Summary: Nilotinib potently inhibits human uridine diphosphate-glucuronosyltransferase (UGT1A1) activity, causing hyperbilirubinemia. We investigated the influence of UGT1A1 polymorphisms and nilotinib plasma trough concentrations (C 0 ) on nilotinib-induced hyperbilirubinemia in 34 Japanese patients with chronic myeloid leukemia (CML). The proportion of patients with hyperbilirubinemia was significantly higher among patients with the UGT1A1*6/*6 and *6/*28 genotypes (poor metabolizers) than among those with other genotypes (p = 0.004). The median time to elevation of bilirubin levels in UGT1A1 poor metabolizers was 2.0 weeks (hazard ratio, 6.11). The median time to reduction in nilotinib dose in UGT1A1 poor metabolizers was 4.0 weeks (hazard ratio, 7.52; p = 0.002). Consequently, in the maintenance phase 3 months following the initiation of nilotinib therapy, the median daily dose and C 0 of nilotinib were 350 mg/day and 372 ng/mL, respectively, in UGT1A1 poor metabolizers, and 600 mg/day and 804 ng/mL, respectively, in the other patients. Patients at increased hyperbilirubinemia risk could be identified by prospective UGT1A1 genotyping prior to nilotinib therapy. To avoid an interruption of CML treatment due to nilotinib-induced hyperbilirubinemia, it may be beneficial to reduce the initial nilotinib dose to 300 400 mg/day for UGT1A1 poor metabolizers.
Introduction
Nilotinib is a second-generation tyrosine kinase inhibitor that was originally developed for the treatment of chronic myeloid leukemia (CML).
1) Nilotinib functions through competitive inhibition at the ATP-binding site of the breakpoint cluster regionAbelson1 (BCR-ABL1) kinase, leading to the inhibition of tyrosine phosphorylation of proteins involved in intracellular signal transduction. 2, 3) In vitro, nilotinib has a higher binding affinity and selectivity for c-ABL kinase than does imatinib, resulting in 30-fold higher potency. [4] [5] [6] Nilotinib is primarily metabolized via CYP3A4 and is a substrate of P-glycoprotein and breast cancer resistance protein. 7) An in vitro study has demonstrated that nilotinib inhibits cytochrome P450 enzymes CYP3A4, CYP2C8, CYP2C9, and CYP2D6, as well as uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1). 8) Bilirubin is a toxic metabolite that predominantly results from the turnover of hemoglobin. In humans, UGT1A1 catalyzes the glucuronidation of bilirubin, forming intermediate mono-and diglucoronides. 9) UGT1A1 is encoded by the UGT1A gene on chromosome 2q37. 10, 11) Polymorphisms in the UGT1A1 gene promoter have been shown to affect transcriptional efficiency, strongly influencing bilirubin metabolism and clearance. 12) The most common promoter sequence contains a (TA)6TAA sequence, while the less frequent *28 allele contains an extended sequence of 7 TA repeats. The UGT1A1*28/*28 genotype is associated with unusually high bilirubin levels. 12, 13) Alleles with five or eight TA repeats have also been described, observed primarily in African populations. The UGT1A1*6 (211G>A) and UGT1A1*27 (686C>A) isoforms have also been reported to cause a reduction in UGT1A1 enzyme activity. 14) However, the UGT1A1*27 allele, detected only in Asian populations, has been reported to be present exclusively in a haplotype with the UGT1A1*28 allele. In the Japanese population, UGT1A1*6/*6, *6/*28, and *28/*28 genotypes, manifesting as reduced-activity polymorphisms, were detected in 1.3, 3.2, and 2.7% of the population, respectively. 15, 16) Nilotinib inhibits bilirubin metabolism via UGT1A1, thereby increasing bilirubin levels. 17) This effect might be particularly pronounced in patients who have the so-called "poor-metabolizer" forms of UGT1A1, such as UGT1A1*6/*6, *6/*28, and *28/*28. Singer et al. reported that patients with the UGT1A1*28/*28 genotype have an elevated risk of nilotinib-induced hyperbilirubinemia compared to those with the UGT1A1*1/*1 and *1/*28 genotypes. 18) In addition, Shibata et al. reported that one patient with the UGT1A1*6/*6 genotype developed Common Terminology Criteria for Adverse Events (CTCAE) grade 2 hyperbilirubinemia. 19) The aim of the current investigation was to examine the impact of UGT1A1 *6, *27, and *28 polymorphisms on nilotinib-induced hyperbilirubinemia in 34 Japanese CML patients. Plasma bilirubin levels were expected to correlate with plasma trough concentration (C 0 ) of nilotinib because of its inhibitory effects on UGT1A1 activity and lower enzymatic activity associated with *6 and *28 UGT1A1 polymorphisms. To investigate this interaction, we evaluated the relationship between nilotinib C 0 and total bilirubin levels in the maintenance phase following the initiation of nilotinib therapy in CML patients.
Methods
Patients and protocols: The 34 Japanese CML patients enrolled in this study were either resistant to or could not tolerate imatinib, or were newly diagnosed (de novo) with CML. All subjects enrolled in the study were patients treated at the Akita University Hospital from June 2009 through February 2013. Patient characteristics at initial nilotinib administration (baseline) are listed in Table 1 . This study was approved by the Ethics Committee of Akita University Graduate School of Medicine. Each participant provided informed consent and signed a human subject institutional review board consent form.
Initially, nilotinib (Tasigna, Novartis Corporation, Tokyo, Japan) was orally administered either once or twice daily at designated times (0900 and 2100 h). The maintenance dosage of nilotinib was adjusted according to the development of side effects. During the study period, the patients were not administered drugs or foods known to affect CYP3A or P-glycoprotein function. At 3, 6, and 12 months after beginning nilotinib therapy, whole blood samples were collected just prior to oral nilotinib administration. In the present study, the maintenance dosage of nilotinib was not changed for two weeks before the monitoring of bilirubin levels was performed. Plasma was isolated by centrifugation at 1,900 © g for 15 min and was stored at ¹40°C until analyzed. The toxicity grade was determined using CTCAE version 4.0.
Analysis of nilotinib plasma concentrations: Plasma concentrations of nilotinib were measured by high-performance liquid chromatography (HPLC). 20) Following the addition of dasatinib (100 ng/10 µL methanol) as an internal standard to a 100-µL plasma sample, the plasma sample was diluted with 900 µL of water and vortexed for 30 s. This mixture was applied to an Oasis HLB extraction cartridge that had been activated previously with methanol and water (1.0 mL each). The cartridge was then washed with 1.0 mL of water and 1.0 mL of 60% methanol in water and eluted with 1.0 mL of 100% methanol. The eluates were evaporated to dryness in a vacuum at 40°C using a rotary evaporator (Iwaki, Tokyo, Japan). The resulting residue was then dissolved in 20 µL of methanol and vortexed for 30 s; 20 µL of the mobile phase was added to the sample, and the sample was vortexed for another 30 s. A 20-µL aliquot of the sample was then processed by HPLC. The HPLC system comprised a PU-2080 plus chromatography pump (JASCO, Tokyo, Japan) equipped with a CAPCELL PAK C18 MG ¬ (250 mm © 4.6 mm I.D., Shiseido, Tokyo, Japan) HPLC column, a UV-2075 light source, and an ultraviolet detector (JASCO). The mobile phase was 0.5% KH 2 PO 4 (pH 2.5)-acetonitrile-methanol (55:25:20, v/v/v), which was degassed in an ultrasonic bath prior to use. The flow rate was 0.5 mL/min at ambient temperature, and sample detection was carried out at 250 nm.
Genotyping: DNA was extracted from peripheral blood samples using a QIAamp Blood Kit (Qiagen, Hilden, Germany) and was stored at ¹80°C until analyzed. We studied the following variant sequences: a 2-nucleotide insertion (TA) within the TATA box resulting in the sequence (TA) 7 TAA (¹39 to ¹53, UGT1A1*28: rs8175347); a transition (+211 from the initial site of the transcription, G to A) at codon 71 in exon 1 that changes glycine to arginine (G71R, UGT1A1*6: rs4148323); and a transversion (+686, C to A) at codon 229 in exon 1 that changes proline to glutamine (P229Q, UGT1A1*27: rs35350960). Genotyping procedures to identify the *6, *27, and *28 alleles of UGT1A1 were performed using the polymerase chain reaction/restriction fragment length polymorphism (PCR-RFLP) method.
14) The PCR-RFLP results were confirmed using a fully automated single nucleotide polymorphism (SNP) detection system (prototype i-densy, Arkray Inc., Kyoto, Japan). The UGT1A1 genotype analysis revealed 6 different patterns, as follows: *1/*1 in 15 patients, *1/*6 in 8 patients, *1/*28 in 5 patients, *1/*27+*1/*28 (*27/*28 in the present study) in 2 patients, *6/*6 in 2 patients and *6/*28 in 2 patients. The patients were divided into 3 groups: group 1 comprised subjects with the UGT1A1*1/*1 genotype (n = 15); group 2 comprised those with UGT1A1*1/*6, *1/*28, and *27/*28 genotypes (n = 15); and group 3 included participants with UGT1A1*6/*6 and 6/*28 genotypes (poor metabolizers; n = 4) ( Table 1) . Statistical analyses: The Kolmogorov-Smirnov test was used to assess distribution. The clinical characteristics of the patients and dosage of nilotinib are expressed as the mean « SD (minimum-maximum), number or median (quartile 1-quartile 3). The » 2 test was used to examine differences in categorical data, and the Mann-Whitney U test was used to determine differences in continuous values between the groups. The time (weeks) until increase in bilirubin levels and reduction of nilotinib dose was measured from the date of nilotinib administration to the date of each event. The proportion of patients showing no elevation in bilirubin levels and the % reduction in nilotinib dose were estimated using the Kaplan-Meier method. The time to clinical event was compared between the groups by using the stratified log-rank test. Spearman's rank correlation coefficient test was employed to assess the correlation between the total bilirubin levels and nilotinib trough concentration. p values less than 0.05 were considered statistically significant. Statistical analysis was performed using SPSS 20.0 for Windows (SPSS IBM Japan Inc., Tokyo, Japan).
Results
Clinical characteristics at the time of the initial nilotinib administration (baseline) were compared between patients with and without elevation of bilirubin levels within 3 months after nilotinib administration ( Table 2) . No significant difference was observed in any laboratory test values at baseline or nilotinib initial dosage between patients with and without elevation of bilirubin levels. However, the proportion of patients with bilirubin levels higher than that associated with CTCAE grade 1 was significantly higher in patients with the UGT1A1*6/*6 and *6/*28 genotypes than in those with other genotypes (p = 0.014) ( Table 2 ). In addition, bilirubin levels tended to increase in the de novo CML patients compared to those with imatinib resistance or intolerance (p = 0.041; Table 2 ).
The UGT1A1 genotype information and characteristics of 10 patients for whom the nilotinib dose was decreased because of adverse events are shown in Table 3 . Of these 10 patients, 7 were given a lower nilotinib dose owing to increased bilirubin levels. Three of the 10 patients experienced other adverse events: One subject had an aggravation of pulmonary fibrosis at 10 weeks after nilotinib intake, one had an elevation in aspartate aminotransferase level at 5 weeks, and one developed a skin rash at 3 weeks. The elevation in bilirubin levels occurred within 12 weeks, and 4 of the 7 patients with elevated bilirubin levels had either UGT1A1*6/*6 or *6/*28 genotypes ( Table 3) . The Kaplan-Meier curve for bili- rubin level elevation is shown in Figure 1A . Within the first 12 weeks of nilotinib administration, bilirubin levels rose higher than those associated with grade 1 in 30% of the patients with the UGT1A1*1/*1, *1/*6, *1/*28, and *27/*28 genotypes. However, the median time to elevation of bilirubin levels in patients with the UGT1A1*6/*6 and *6/*28 genotypes was 2.0 weeks (hazard ratio, 6.11; p = 0.004). Only 20% of the patients with the UGT1A1*1/ *1, *1/*6, *1/*28, and *27/*28 genotypes were given a lower dose of nilotinib within the first 12 weeks of nilotinib administration. The median time to decreasing the nilotinib dose in patients with the UGT1A1*6/*6 and *6/*28 genotypes was 4.0 weeks (hazard ratio, 7.52 vs. patients with the UGT1A1*1/*1, *1/*6, *1/*28, and *27/*28 genotypes; p = 0.002; Fig. 1B ).
In the maintenance phase 3 months after the beginning of nilotinib administration, the median daily dose and the C 0 of nilotinib in the patients with the UGT1A1*1/*1, *1/*6, *1/*28, and *27/*28 genotypes were 600 mg/day and 804 ng/ mL, respectively, while the corresponding values in subjects with UGT1A1*6/*6 or *6/*28 genotypes were 350 mg/day and 372 ng/mL, respectively ( Table 4) . At 12 months after the beginning of nilotinib administration, the median daily dose and the C 0 of nilotinib in the patients with the UGT1A1*1/*1, *1/*6, *1/*28, and *27/*28 genotypes were 600 mg/day and 766 ng/ mL, respectively, the corresponding values in participants with the UGT1A1*6/*6 and *6/*28 genotypes were 300 mg/day and 392 ng/mL, respectively ( Table 4) .
The correlation between the nilotinib C 0 and total bilirubin levels at the maintenance phase is shown in Figure 2 . The r 2 between nilotinib C 0 and total bilirubin levels in patients with the UGT1A1*1/*1, *1/*6, *1/*28, and *27/*28 genotypes and compared to those with the UGT1A1*6/*6 and *6/*28 genotypes were 0.184 and 0.107, respectively (p < 0.001 and p = 0.127, respectively).
Discussion
Bilirubin levels rose in the early stage of nilotinib administration Fig. 1 . Kaplan-Meier curves representing the timing of (A) the elevation of bilirubin levels and (B) the decrease in nilotinib dose Unbroken line, patients with the UGT1A1*1/*1, *1/*6, and *1/*28 genotypes; dotted line, patients with the UGT1A1*6/*6, *6/*28, and *27/*28 genotypes. Table 4 . Comparison of dosage and trough concentration of nilotinib, and total bilirubin levels between UGT1A1 genotypes in the maintenance phase
Length of nilotinib treatment (months)
*1/*1 + *1/*6 + *1/*28 + *27/*28 *6/*6 + *6/*28 Maximum value of total bilirubin levels, Median (minimum-maximum); n, patient number; Q1-Q3, quartile 1-quartile 3.
in CML patients with the UGT1A1*6/*6 and *6/*28 genotypes. The influence of UGT1A1 inhibition by nilotinib seems to appear within 1-3 weeks after the start of nilotinib administration. This finding suggests that patients with an increased risk of hyperbilirubinemia could be identified by prospective genotyping of UGT1A1 prior to initiation of nilotinib therapy. Although three of the CML patients enrolled in this study experienced other adverse events, including pulmonary fibrosis, an elevation in aspartate aminotransferase levels, and a skin rash, we observed no relationship between the nilotinib-induced adverse events and the individual UGT1A1 polymorphisms. As a result of hyperbilirubinemia, the daily nilotinib dose during the maintenance phase (after 3 months of nilotinib therapy) for patients with the UGT1A1*6/*6 or *6/*28 genotypes was about 300-400 mg/day, lower than that for patients with the UGT1A1*1/*1, *1/*6, *1/*28, or *27/*28 genotypes (600 mg/day). In the patients with the UGT1A1*6/*6 or *6/*28 genotypes, the median C 0 of nilotinib at 12 months of treatment was 392 ng/mL. Fortunately, all 10 patients who received a lower nilotinib dose owing to development of adverse events achieved a major molecular response (MMR) at 12 months, which was predictive of progression-free survival as an optimal response. 21) In the patients with UGT1A1*6/*6, *6/*28, or *28/ *28 genotypes, reportedly comprising 8.8% of the Japanese population, 16) reduction of the initial dose of nilotinib to 300-400 mg/day may be necessary to prevent nilotinib-induced hyperbilirubinemia and to avoid an interruption of CML treatment due to hyperbilirubinemia, especially in those with de novo CML.
On the other hand, the median nilotinib C 0 at 12 months of treatment was 766 ng/mL in the patients who are homozygous and heterozygous carriers of the UGT1A1*1 allele. As shown in Figure 1B , the decrease in nilotinib dosage in the patients with these genotypes was only 20% following 12 weeks of treatment, and all of these patients achieved MMR within 12 months. Giles et al. reported that patients with nilotinib C 0 above 500 ng/mL have a significantly shorter time to achieve the cytogenetic response or MMR. 22) As with imatinib, therapeutic drug monitoring to maintain a target plasma concentration might be beneficial during nilotinib therapy. Future prospective studies should focus on establishing a recommended nilotinib C 0 range for achieving an optimal response during CML treatment.
Since nilotinib is a potent non-competitive inhibitor of UGT1A1, 17) we evaluated the relationship between nilotinib C 0 and total bilirubin levels measured in the maintenance phase following the initiation of nilotinib therapy. The correlation was found to be very low, although nilotinib C 0 was significantly associated with total bilirubin levels in patients homozygous and heterozygous for the UGT1A1*1 allele. On the other hand, the slope of the correlation between nilotinib C 0 and total bilirubin levels in CML patients with the UGT1A1*6/*6 or *6/*28 genotypes was greater than the slope in those with the UGT1A1*1/*1, *1/*6, *1/*28, or *27/*28 genotypes. The higher slope observed with the data from the patients who were UGT1A1 poor metabolizers therefore suggests an additive contribution of the UGT1A1 genetic factor in increasing bilirubin levels. This finding indicates that nilotinib sufficiently inhibits UGT1A1 even at low C 0 in patients having the UGT1A1*6/*6, *6/*28, and *28/*28 genotypes and shows why the nilotinib dosage and C 0 were lower in the patients with the UGT1A1*6/*6, *6/*28, and *28/*28 genotypes than in those without. In the present study, we monitored the total plasma concentration of nilotinib. If plasma concentrations of only unbound nilotinib were measured, showing hepatic input concentrations of nilotinib, a higher correlation between the nilotinib C 0 and total bilirubin levels might be observed. A prospective analysis of UGT1A1 polymorphisms and monitoring of unbound plasma concentrations after nilotinib initiation might improve the outcome of nilotinib therapy.
In this study, we observed that the combined effect of UGT1A1 activity inhibition by nilotinib and genetic polymorphisms of UGT1A1 is very important. In the case of substrates having two metabolic pathways, the plasma concentrations of substrates in patients who are poor metabolizers for one enzyme does not increase as much, even if drug-drug interaction via this enzyme occurs, because another metabolic pathway is available. The majority of substrates are glucuronidated by multiple UGT enzymes; however, the endogenous substance bilirubin is selectively glucuronidated by UGT1A1, and patients who carry homozygous alleles that express the UGT1A1 allelic variant can develop severe unconjugated hyperbilirubinemia even without nilotinib treatment. 10 ) Therefore, UGT1A1 polymorphisms should be analyzed prior to initiation of nilotinib therapy.
Our results must be interpreted within the context of the study limitations. In this study, it was difficult to evaluate the relationship between nilotinib C 0 and clinical responses because more than 70% of the patients had been treated with imatinib and had achieved clinical responses before the administration of nilotinib. Further examination with a larger sample size will be necessary to corroborate the study results.
In conclusion, patients at increased risk of hyperbilirubinemia could be identified by prospective genotyping of UGT1A1 prior to initiation of nilotinib therapy. To avoid an interruption of CML treatment due to nilotinib-induced hyperbilirubinemia, it may be advisable to reduce the initial nilotinib dose to 300-400 mg/day for UGT1A1 poor metabolizers who have the UGT1A1*6/*6, *6/*28, or *28/*28 genotypes. The correlation between nilotinib C 0 and total bilirubin levels in the maintenance phase after the beginning of therapy Open circles, patients with UGT1A1*1/*1, *1/*6, *1/*28, or *27/*28 genotypes; closed circles, patients with the UGT1A1*6/*6 or *6/*28 genotypes.
